Skip to content

Research at St Andrews

Ischemia-modified albumin: crosstalk between fatty acid and cobalt binding

Research output: Contribution to journalReview article

Standard

Ischemia-modified albumin : crosstalk between fatty acid and cobalt binding. / Coverdale, James P. C.; Katundu, Kondwani G. H.; Sobczak, Amélie Isabelle Sylvie; Arya, Swati; Blindauer, Claudia A.; Stewart, Alan J.

In: Prostaglandins, Leukotrienes and Essential Fatty Acids, Vol. 135, 08.2018, p. 147-157.

Research output: Contribution to journalReview article

Harvard

Coverdale, JPC, Katundu, KGH, Sobczak, AIS, Arya, S, Blindauer, CA & Stewart, AJ 2018, 'Ischemia-modified albumin: crosstalk between fatty acid and cobalt binding', Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 135, pp. 147-157. https://doi.org/10.1016/j.plefa.2018.07.014

APA

Coverdale, J. P. C., Katundu, K. G. H., Sobczak, A. I. S., Arya, S., Blindauer, C. A., & Stewart, A. J. (2018). Ischemia-modified albumin: crosstalk between fatty acid and cobalt binding. Prostaglandins, Leukotrienes and Essential Fatty Acids, 135, 147-157. https://doi.org/10.1016/j.plefa.2018.07.014

Vancouver

Coverdale JPC, Katundu KGH, Sobczak AIS, Arya S, Blindauer CA, Stewart AJ. Ischemia-modified albumin: crosstalk between fatty acid and cobalt binding. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2018 Aug;135:147-157. https://doi.org/10.1016/j.plefa.2018.07.014

Author

Coverdale, James P. C. ; Katundu, Kondwani G. H. ; Sobczak, Amélie Isabelle Sylvie ; Arya, Swati ; Blindauer, Claudia A. ; Stewart, Alan J. / Ischemia-modified albumin : crosstalk between fatty acid and cobalt binding. In: Prostaglandins, Leukotrienes and Essential Fatty Acids. 2018 ; Vol. 135. pp. 147-157.

Bibtex - Download

@article{d840a029870f4a12859131bbcb78b993,
title = "Ischemia-modified albumin: crosstalk between fatty acid and cobalt binding",
abstract = "Myocardial ischemia is difficult to diagnose effectively with still few well-defined biochemical markers for identification in advance, or in the absence of myocardial necrosis. “Ischemia-modified albumin” (IMA), a form of albumin displaying reduced cobalt-binding affinity, is significantly elevated in ischemic patients, and the albumin cobalt-binding (ACB) assay can measure its level indirectly. Elucidating the molecular mechanism underlying the identity of IMA and the ACB assay hinges on understanding metal-binding properties of albumin. Albumin binds most metal ions and harbours four primary metal binding sites: site A, site B, the N-terminal site (NTS), and the free thiol at Cys34. Previous efforts to clarify the identity of IMA and the causes for its reduced cobalt-binding capacity were focused on the NTS site, but the degree of N-terminal modification could not be correlated to the presence of ischemia. More recent work suggested that Co2+ ions as used in the ACB assay bind preferentially to site B, then to site A, and finally to the NTS. This insight paved the way for a new consistent molecular basis of the ACB assay: albumin is also the main plasma carrier for free fatty acids (FFAs), and binding of a fatty acid to the high-affinity site FA2 results in conformational changes in albumin which prevent metal binding at site A and partially at site B. Thus, this review advances the hypothesis that high IMA levels in myocardial ischemia and many other conditions originate from high plasma FFA levels hampering the binding of Co2+ to sites A and/or B. This is supported by biophysical studies and the co-association of a range of pathological conditions with positive ACB assays and high plasma FFA levels.",
keywords = "Albumin cobalt binding assay, Molecular diagnostics, Free fatty acids, Human serum albumin, Myocardial ischaemia",
author = "Coverdale, {James P. C.} and Katundu, {Kondwani G. H.} and Sobczak, {Am{\'e}lie Isabelle Sylvie} and Swati Arya and Blindauer, {Claudia A.} and Stewart, {Alan J.}",
note = "This work was supported by the Leverhulme Trust (grant ref. RPG-2017-214), BBSRC (grant ref. BB/J006467/1) and the British Heart Foundation (grant refs. PG/15/9/31270 and FS/15/42/31556).",
year = "2018",
month = "8",
doi = "10.1016/j.plefa.2018.07.014",
language = "English",
volume = "135",
pages = "147--157",
journal = "Prostaglandins, Leukotrienes and Essential Fatty Acids",
issn = "0952-3278",
publisher = "Elsevier",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Ischemia-modified albumin

T2 - crosstalk between fatty acid and cobalt binding

AU - Coverdale, James P. C.

AU - Katundu, Kondwani G. H.

AU - Sobczak, Amélie Isabelle Sylvie

AU - Arya, Swati

AU - Blindauer, Claudia A.

AU - Stewart, Alan J.

N1 - This work was supported by the Leverhulme Trust (grant ref. RPG-2017-214), BBSRC (grant ref. BB/J006467/1) and the British Heart Foundation (grant refs. PG/15/9/31270 and FS/15/42/31556).

PY - 2018/8

Y1 - 2018/8

N2 - Myocardial ischemia is difficult to diagnose effectively with still few well-defined biochemical markers for identification in advance, or in the absence of myocardial necrosis. “Ischemia-modified albumin” (IMA), a form of albumin displaying reduced cobalt-binding affinity, is significantly elevated in ischemic patients, and the albumin cobalt-binding (ACB) assay can measure its level indirectly. Elucidating the molecular mechanism underlying the identity of IMA and the ACB assay hinges on understanding metal-binding properties of albumin. Albumin binds most metal ions and harbours four primary metal binding sites: site A, site B, the N-terminal site (NTS), and the free thiol at Cys34. Previous efforts to clarify the identity of IMA and the causes for its reduced cobalt-binding capacity were focused on the NTS site, but the degree of N-terminal modification could not be correlated to the presence of ischemia. More recent work suggested that Co2+ ions as used in the ACB assay bind preferentially to site B, then to site A, and finally to the NTS. This insight paved the way for a new consistent molecular basis of the ACB assay: albumin is also the main plasma carrier for free fatty acids (FFAs), and binding of a fatty acid to the high-affinity site FA2 results in conformational changes in albumin which prevent metal binding at site A and partially at site B. Thus, this review advances the hypothesis that high IMA levels in myocardial ischemia and many other conditions originate from high plasma FFA levels hampering the binding of Co2+ to sites A and/or B. This is supported by biophysical studies and the co-association of a range of pathological conditions with positive ACB assays and high plasma FFA levels.

AB - Myocardial ischemia is difficult to diagnose effectively with still few well-defined biochemical markers for identification in advance, or in the absence of myocardial necrosis. “Ischemia-modified albumin” (IMA), a form of albumin displaying reduced cobalt-binding affinity, is significantly elevated in ischemic patients, and the albumin cobalt-binding (ACB) assay can measure its level indirectly. Elucidating the molecular mechanism underlying the identity of IMA and the ACB assay hinges on understanding metal-binding properties of albumin. Albumin binds most metal ions and harbours four primary metal binding sites: site A, site B, the N-terminal site (NTS), and the free thiol at Cys34. Previous efforts to clarify the identity of IMA and the causes for its reduced cobalt-binding capacity were focused on the NTS site, but the degree of N-terminal modification could not be correlated to the presence of ischemia. More recent work suggested that Co2+ ions as used in the ACB assay bind preferentially to site B, then to site A, and finally to the NTS. This insight paved the way for a new consistent molecular basis of the ACB assay: albumin is also the main plasma carrier for free fatty acids (FFAs), and binding of a fatty acid to the high-affinity site FA2 results in conformational changes in albumin which prevent metal binding at site A and partially at site B. Thus, this review advances the hypothesis that high IMA levels in myocardial ischemia and many other conditions originate from high plasma FFA levels hampering the binding of Co2+ to sites A and/or B. This is supported by biophysical studies and the co-association of a range of pathological conditions with positive ACB assays and high plasma FFA levels.

KW - Albumin cobalt binding assay

KW - Molecular diagnostics

KW - Free fatty acids

KW - Human serum albumin

KW - Myocardial ischaemia

U2 - 10.1016/j.plefa.2018.07.014

DO - 10.1016/j.plefa.2018.07.014

M3 - Review article

VL - 135

SP - 147

EP - 157

JO - Prostaglandins, Leukotrienes and Essential Fatty Acids

JF - Prostaglandins, Leukotrienes and Essential Fatty Acids

SN - 0952-3278

ER -

Related by author

  1. On the origin of proteins in human drusen: the meet, greet and stick hypothesis

    Bergen, A. A., Arya, S., Koster, C., Pilgrim, M. G., Wiatrek-Moumoulidis, D., van der Spek, P., Hauck, S. M., Boon, C. J. F., Emri, E., Stewart, A. J. & Lengyel, I., May 2019, In : Progress in Retinal and Eye Research. 70, p. 55-84 30 p.

    Research output: Contribution to journalArticle

  2. Crosstalk between zinc and fatty acids in plasma

    Coverdale, J. P. C., Khazaipoul, S., Arya, S., Stewart, A. J. & Blindauer, C. A., Apr 2019, In : Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids. 1864, 4, p. 532-542 11 p.

    Research output: Contribution to journalReview article

  3. Quantitative analysis of hydroxyapatite-binding plasma proteins in genotyped individuals with late-stage age-related macular degeneration

    Arya, S., Emri, E., Synowsky, S. A., Shirran, S. L., Barzegar-Befroei, N., Peto, T., Botting, C. H., Lengyel, I. & Stewart, A. J., Jul 2018, In : Experimental Eye Research. 172, p. 21-29 9 p.

    Research output: Contribution to journalArticle

  4. A metalloproteomic analysis of interactions between plasma proteins and zinc: elevated fatty acid levels affect zinc distribution

    Coverdale, J. P. C., Barnett, J. P., Adamu, A. H., Griffiths, E. J., Stewart, A. J. & Blindauer, C. A., 15 Oct 2019, In : Metallomics. Advance Article, p. 1-15 15 p.

    Research output: Contribution to journalArticle

ID: 254989571

Top